Bruker (BRKR) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $8.65B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Frank H. Laukien |
| IPO Date | 2000-08-04 | CAGR | 17.7% |
| Employees | 11,085 | Website | www.bruker.com |
| Div. Yield | 0.09% | Payout Ratio | -59% |
| Buy Back Yield | — | Total Yield | 0.09% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $11.60B | P/E | 28.57 | Forward P/E | 23.62 | PEG | — |
| P/S | 9.28 | P/B | 13.47 | P/CF | 170.32 | P/FCF | 345.43 |
| Sales | $3.50B | Sales 1Y | 1.65% | Sales 3Y | 28.92% | Sales 5Y | 54.55% |
| EPS | $1.99 | EPS 1Y | -234.44% | EPS 3Y | -132.37% | EPS 5Y | -145.1% |
| Sales QoQ | 1.83% | EPS QoQ | -1890.39% | Sales QoQ Avg | 1.89% | EPS QoQ Avg | -752.73% |
| Gross Margin | 46.42% | Operating Margin | 2.62% | Profit Margin | -2.66% | ROCE | 1.89% |
| ROA | -2% | ROE | -4% | Altman Z Score | 2.53 | Piotroski Score | 5 |
| Current Ratio | 1.85 | Quick Ratio | 0.92 | Cash Ratio | 0.15 | Op. CF Ratio | -0.06 |
| Debt/Equity | 0.76 | Debt/Assets | 0.3 | Lt Debt/Equity | 0.76 | Lt Debt/Cap. | 0.43 |
| Intrst Cov. | 1.35 | Inventory Turnover | 1.67 | Asset Turnover | 0.58 | Receivables Turnover | 6.41 |
| Enterprise Value | $11.60B | P/E Ratio | 28.57 |
| Forward P/E | 23.62 | PEG Ratio | — |
| P/S Ratio | 9.28 | P/B Ratio | 13.47 |
| P/CF Ratio | 170.32 | P/FCF Ratio | 345.43 |
| EPS | $1.99 | EPS Growth 1Y | -234.44% |
| EPS Growth 3Y | -132.37% | EPS Growth 5Y | -145.1% |
| Revenue Growth 1Y | 1.65% | Gross Margin | 0.46% |
| Operating Margin | 0.03% | Profit Margin | -0.03% |
| ROE | -0.04% | ROA | -0.02% |
| ROCE | 0.02% | Current Ratio | 1.85 |
| Quick Ratio | 0.92 | Cash Ratio | 0.15 |
| Debt/Equity | 0.76 | Interest Coverage | 1.35 |
| Altman Z Score | 2.53 | Piotroski Score | 5 |
Bruker (BRKR) valuation & financials
Bruker (BRKR) has a market capitalization of $8.65B and trades at a price-to-earnings ratio of 28.6. It operates in the Healthcare sector (Medical - Devices).
Bruker's revenue grew +1.6% over the last year.
Bruker's next earnings report is scheduled for November 2, 2026 before market open; analysts estimate EPS of $0.42. Check the earnings calendar to see all companies reporting this week.
Bruker (BRKR) — frequently asked questions
When does Bruker (BRKR) report earnings next?
Bruker is expected to report earnings on November 2, 2026 before market open. Analysts estimate EPS of $0.42.
What is Bruker's market cap?
Bruker (BRKR) has a market capitalization of $8.65B.
What is BRKR's P/E ratio?
Bruker trades at a price-to-earnings ratio of 28.6, with trailing twelve-month EPS of $1.99.
How fast is Bruker growing?
Bruker's revenue grew +1.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)